Mellema WW et al. [43] retrospectively analyzed 464 KRAS mutated NSCLC patients, and found patients treated with taxanes had a significant improved ORR (50%) compared to pemetrexed (21%) or gemcitabine (25%; P < 0.01). Here, KRAS is linked to non-small cell lung carcinoma.